Chafic Karam, MD
Professor of Clinical Neurology
Neuromuscular Fellowship Director, University of Pennsylvania
Neurology CME course director, University of Pennsylvania
Chief, Neuromuscular Division, University of Pennsylvania
Department: Neurology
Contact information
3400 Spruce St., 3 West Gates
Philadelphia, PA 19104
Philadelphia, PA 19104
Office: 2156153751
Fax: 2153495579
Fax: 2153495579
Publications
Education
MD
St Joseph University, 2006.
MD
St Joseph University, 2006.
Post-Graduate Training
Intern, Hotel Dieu de France, 2006-2007.
Intern, Mount Sinai Beth Israel, 2007-2008.
Resident in Neurology, Mount Sinai Beth Israel, 2008-2011.
Fellow in Neuromuscular Disorders, Harvard Neurology at Brigham and Women's Hospital and Massachusetts General Hospital., 2011-2012.
Fellow in Peripheral Nerve Disorders, Mayo Clinic, 2012-2013.
Intern, Hotel Dieu de France, 2006-2007.
Intern, Mount Sinai Beth Israel, 2007-2008.
Resident in Neurology, Mount Sinai Beth Israel, 2008-2011.
Fellow in Neuromuscular Disorders, Harvard Neurology at Brigham and Women's Hospital and Massachusetts General Hospital., 2011-2012.
Fellow in Peripheral Nerve Disorders, Mayo Clinic, 2012-2013.
Certifications
American Board of Psychiatry and Neurology, Neurology Certificate No. 56979 , 2011.
American Board of Psychiatry and Neurology Neuromuscular Medicine Certificate No. 557 , 2012.
United Council for Neurologic Subspecialties Clinical Neuromuscular Pathology Certification , 2015.
Permanent linkAmerican Board of Psychiatry and Neurology, Neurology Certificate No. 56979 , 2011.
American Board of Psychiatry and Neurology Neuromuscular Medicine Certificate No. 557 , 2012.
United Council for Neurologic Subspecialties Clinical Neuromuscular Pathology Certification , 2015.
Description of Clinical Expertise
CIDP, MMN, Amyloid Neuropathy.Selected Publications
Allen JA, Eftimov F, Querol L, Sommer C, Dimachkie MM, Fix C, Gable K, Gorson KC, Harbo T, Karam C, Koike H, Kuitwaard K, Lunn MP, Nobile-Orazio E, Pasnoor M, Rajabally YA, Peric S, Reisin R, Butler L; : Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Neurology 2026 Jul 14;107(1):e218159.Jakobsen J, Karam C, Kuitwaard K, Levine T. : A Practical Guide to Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Neurol Ther. 2026 Jul 11. July 2026.
Dvorak JE, Khella S, Drachman B, Row R, Pieretti J, Mathelier H, Karam C. : Polyneuropathy in p.V142I hereditary transthyretin amyloidosis: Diagnostic challenges and clinical considerations J Neurol Sci. Jun 2026.
Donofrio PD, Gorson KC, Hofman E, Karam C, Kira JI, Kostera-Pruszczyk A, Léger JM, Nobile-Orazio E, Attarian S, Markov M, Tse A, De Roeck A, Lewis RA.: Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20 J Neurol Sci. Apr 2026.
John E. Dvorak, Sami Khella, Brian Drachman, Rebecca Row, Janice Pieretti, Hansie Mathelier, Chafic Karam: Prevalence and attribution of polyneuropathy in p.V142I (V122I) hereditary transthyretin amyloidosis. Journal of the Neurological Sciences April 2026.
Joban Vaishnav, Dimitrios Bampatsias, Brian C. Boursiquot, Yevgeniy Brailovsky, Kristin Hsu, Jamie Zigterman, Rajshekhar Chakraborty, Ashutosh Wechalekar, Pablo Garcia Pavia, Ronald Witteles, Mazen Hanna, Chafic Karam, Mathew S. Maurer, and Jan M. Griffin : Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology 8(2), April 2026.
Karam C.: Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy. Muscle Nerve. Page: 73(1):86-92. Jan 2026.
Chakraborty R, Brailovsky Y, Hanna M, Witteles R, Vaishnav J, Hoffman JE, Griffin JM, Garcia-Pavia P, Wolinsky D, Karam C, Lachmann HJ, Gertz MA, Boursiquot BC, Bampatsias D, Hsu K, Johnson PT, Zigterman JL, Kazemzadeh AC, Maurer MS, Wechalekar AD.: Prognostic Factors and Progression Biomarkers in AL Amyloidosis: Mapping Current Knowledge and Critical Gaps Blood. 2026 Mar 4:blood.2025031651. 2026.
Vu T, Durmus H, Rivner M, Shroff S, Ragole T, Myers B, Pasnoor M, Small G, Karam C, Vullaganti M, Peltier A, Sahagian G, Feinberg MH, Slanksy A, Barnett-Tapia C, Siddiqi Z, Gwathmey K, Badruddoja MA, Kamboh H, Ruggerie RN, Fedak RR, Stewart CA, Kurtoglu M, Kalayoglu M, Singer M, Jewell CM, Miljkovic MD, Dimachkie M, Mozaffar T, Howard JF Jr; MG-001 Study Team.: BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2026.
Blein C, Karam C, Arvin-Berod C, Gelinas D, Barrera-Sierra S, Syed HUTA, Ward C, Goyal A, Guptill J.: Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States. Front Neurol. 2026 Jan 29;16:1726857 2026.